Table 1 Studies on patients with mastocytosis treated with Omalizumab
Study | PTs (n) | Age (yr) | Dose | Therapy lenght | Total IgE | Tryptase ng/ml |
|---|---|---|---|---|---|---|
Systemic Mastocytosis | ||||||
Carter et al., 2007 [17] | 2 | 17 /51 | 300 mg/4 wk | 5.5/4 yrs | ↓ | = |
Pitt et al., 2010 [32]a | 1 | 15 | 300 mg/4 wk | 14 mos | ↓ | = |
Kontou-Fili et al., 2010 [19] | 1 | 48 | 300 mg/4 wk. | 2 yrs | na | ↓ |
Douglass et al., 2010 [31] | 1 | 54 | 150 mg/4 wk | 14 mos | na | ↓ |
Molderings et al., 2011 [21] | 2 | 48/ 53 | 150 mg/4 wk. | 4.5/6 mos | na | ↓ |
Kibsgaard et al., 2014 [23] | 1 | 31 | 300 mg/4 wk | 15 mos | na | = |
Lieberoth et al., 2015 [25] | 2 | 48/57 | 300 mg/4 wk. | 11/15 mos | na | na |
Constantine et al., 2018 [26] | 2 | 29/62 | 300 mg/4 wk | 12 yrs | ↑ | =/↓ |
Broesby-Olsen et al.,2018 [27] | 11 | 26-48 | 75-300 mg/2-4 wk | 1-73 mos | na | = |
Slapnicar et al., 2019 [28] | 6 | 38-75 | 300 mg/2-4 wk. | 3mos/2 yrs | = | ↓/↑ |
Lemal et al., 2019 [29] | 29 | 17-93 | 300 mg/2-4 wk | 2-40 mos | ↑ | = |
Distler et al., 2020 [31] | 5 | 24-67 | 150 mg/4wk | 6 mos | na | = |
Cutaneous Mastocytosis | ||||||
Siebenhaar et al., 2007 [18] | 1 | 56 | 150 mg/2-4 wk | 12 mos | na | na |
Bell et al., 2012 [33]a | 1 | 11 | 150 mg/4 wk | 10 mos | na | na |
Matito et al., 2013 [34]a | 1 | 12 | 450 mg/4 wk | 3 mos | na | na |
Paraskevopoulos et al., 2013 [22] | 1 | 25 | 300 mg/4-7 wk | 2 yrs | na | na |
Sokol et al., 2014 [24] | 1 | 77 | 375 mg/4 wks | 12 mos | na | ↓ |
Hughes et al., 2018 [35]a | 2 | 2 | 150 mg/4 wk | 3 mos | na | = |
Hinnojosa et al., 2019 [30] | 2 | 51/36 | 300 mg/4 wk | 7/5 mos | na | na |
Lemal et al., 2019 [29] | 11 | 17-93 | 300 mg/4 wk | 2-40 mos | ↑ | = |